LUMIPULSE全自动免疫分析检测脑脊液核心AD生物标志物的验证
该研究评估了LUMIPULSE G全自动免疫分析仪检测脑脊液tTau、pTau、Aβ1-42及Aβ1-42/Aβ1-40比值的分析性能,并与INNOTEST ELISA、V-PLEX Plus及LC-MS参考方法比较。结果显示各检测相关性强(r>0.93),重复性CV 2.0-5.6%,再现性CV 2.1-6.5%,并确定了AD诊断的临床cutpoint。结论认为该检测适合临床实验室实践。
要点
- LUMIPULSE G检测与现有免疫分析方法及LC-MS参考方法相关性良好(r>0.93)。
- 重复性CV 2.0-5.6%,再现性CV 2.1-6.5%,最高变异分别见于Aβ1-40和Aβ1-42。
- 确定的AD诊断cutpoint:tTau 409 ng/L,pTau 181 50.2 ng/L,Aβ1-42 526 ng/L,Aβ1-42/Aβ1-40比值0.072。
核心结论
- LUMIPULSE G检测脑脊液AD核心生物标志物适合临床实验室实践,并印证了先前提出的参考限。
研究设计与样本
- 将LUMIPULSE G检测与INNOTEST ELISA(hTau Ag、pTau 181、β-amyloid 1-42)、V-PLEX Plus Aβ Panel 1(6E10)(Aβ1-42/Aβ1-40)及LC-MS参考方法(Aβ1-42)进行比较。
- 评估所有检测的批内和批间实验室再现性。
- 通过分析三个临床诊断患者队列共651份脑脊液样本确定Aβ1-42、tTau和pTau的临床cutpoint;通过2,782份脑脊液样本的混合模型分析确定Aβ1-42/Aβ1-40比值cutpoint。
主要发现
- LUMIPULSE G检测与所有其他免疫分析方法强相关(所有检测r>0.93)。
- 重复性(批内实验室)CV范围为2.0%至5.6%,最高变异见于β-amyloid 1-40。
- 再现性(批间实验室)CV范围为2.1%至6.5%,最高变异见于β-amyloid 1-42。
- AD临床cutpoint:total tau 409 ng/L,pTau 181 50.2 ng/L,β-amyloid 1-42 526 ng/L,Aβ1-42/Aβ1-40比值0.072。
关键数值与推荐
- AD临床cutpoint:total tau 409 ng/L,pTau 181 50.2 ng/L,β-amyloid 1-42 526 ng/L。
- Aβ1-42/Aβ1-40比值cutpoint为0.072。
- 重复性CV 2.0-5.6%,再现性CV 2.1-6.5%。
临床怎么用
- LUMIPULSE G全自动免疫分析仪可用于临床实验室检测脑脊液AD核心生物标志物。
- 可采用本研究确定的cutpoint辅助AD诊断,但需注意方法学差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The core cerebrospinal fluid (CSF) biomarkers; total tau (tTau), phospho-tau (pTau), amyloid β 1-42 (Aβ 1-42), and the Aβ 1-42/Aβ 1-40 ratio have transformed Alzheimer's disease (AD) research and are today increasingly used in clinical routine laboratories as diagnostic tools. Fully automated immunoassay instruments with ready-to-use assay kits and calibrators has simplified their analysis and improved reproducibility of measurements. We evaluated the analytical performance of the fully automated immunoassay instrument LUMIPULSE G (Fujirebio) for measurement of the four core AD CSF biomarkers and determined cutpoints for AD diagnosis. METHODS: Comparison of the LUMIPULSE G assays was performed with the established INNOTEST ELISAs (Fujirebio) for hTau Ag, pTau 181, β-amyloid 1-42, and with V-PLEX Plus Aβ Peptide Panel 1 (6E10) (Meso Scale Discovery) for Aβ 1-42/Aβ 1-40, as well as with a LC-MS reference method for Aβ 1-42. Intra- and inter-laboratory reproducibility was evaluated for all assays. Clinical cutpoints for Aβ 1-42, tTau, and pTau was determined by analysis of three cohorts of clinically diagnosed patients, comprising 651 CSF samples. For the Aβ 1-42/Aβ 1-40 ratio, the cutpoint was determined by mixture model analysis of 2,782 CSF samples. RESULTS: The LUMIPULSE G assays showed strong correlation to all other immunoassays (r>0.93 for all assays). The repeatability (intra-laboratory) CVs ranged between 2.0 and 5.6%, with the highest variation observed for β-amyloid 1-40. The reproducibility (inter-laboratory) CVs ranged between 2.1 and 6.5%, with the highest variation observed for β-amyloid 1-42. The clinical cutpoints for AD were determined to be 409 ng/L for total tau, 50.2 ng/L for pTau 181, 526 ng/L for β-amyloid 1-42, and 0.072 for the Aβ 1-42/Aβ 1-40 ratio. CONCLUSIONS: Our results suggest that the LUMIPULSE G assays for the CSF AD biomarkers are fit for purpose in clinical laboratory practice. Further, they corroborate earlier presented reference limits for the biomarkers.
引用
- Gobom J, Parnetti L, Rosa-Neto P, et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2021. PMID: 34773730. doi:10.1515/cclm-2021-0651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。